GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

You may have been too young to remember, but depending on your state’s school immunization requirements, you likely received ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

In most cases, adequate hydration and over-the-counter pain relievers can help manage your symptoms during the week or two it ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

We get the latest guidance on how to survive the viral season.

Respiratory virus season is arriving, once again, and the La Plata County Public Health Department is urging residents to ...

Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...

The public, by and large, has not been on board with immunizations in the aftermath of the pandemic, despite public health ...

RSV rates can be expected to increase, and flu, as well as other common viruses. Human metapneumovirus tends to peak in ...